Paradigm CEO, Dr. Robert Penny to Address Moffitt Personalized Medicine Program

May 17, 2014, 11:30 ET from Paradigm

ANN ARBOR, Mich. and PHOENIX, May 17, 2014 /PRNewswire-USNewswire/ -- Paradigm today announced that Dr. Robert Penny, CEO, will speak at the Moffitt Cancer Center Personalized Medicine Program: Beyond the Promise: Addressing Evidence and Value in Personalized Medicine on Saturday, May 17th, 2014 at 1:00 p.m. EDT in Tampa, FL.

Paradigm's next-generation sequencing-based test PCDx, analyzes the DNA and RNA (the cancer cell's blueprint genomic landscape) from solid tumors and matches them with relevant targeted therapies and associated clinical trials.

Dr. Penny's talk will focus on the evolution of molecular testing over the past ten years and address the clinical promises of the most current molecular platforms used for the generation of patient-specific molecular data that facilitates matching patients to specific anti-tumor agents.

"I am thrilled about the opportunity to present my perspective on the evolution of personalized medicine as well as my most recent efforts regarding Paradigm PCDx; truly a next-generation cancer test," noted Dr. Penny, M.D., Ph.D. "Our ability to interrogate the patient's tumor for DNA mutations, DNA copy number variations, chromosomal changes and mRNA gene expression with next-generation sequencing at a 3000x depth of coverage, the highest commercially available, in only 4-5 business days is a real differentiator in helping to improve patient care."


Paradigm is a non-profit molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient's cancer and potential therapies based on the specific characterization of the patient's tumor that can impact the patient's course of treatment. Paradigm's Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit

Logo -

SOURCE Paradigm